Novo Nordisk Gains 4.7% as FDA Cracks Down on $49 Copycat Semaglutide
Novo Nordisk shares rose 4.7% in early trading after the FDA vowed to crack down on mass-marketed, unapproved GLP-1 copycat drugs. The rally follows Hims & Hers’s launch of a $49/month compounded semaglutide pill, which Novo Nordisk says may trigger legal challenges.
1. FDA Announces Enforcement Action
The U.S. Food and Drug Administration pledged to target illegal, mass-marketed GLP-1 copycat drugs, including compounded semaglutide pills sold without approval. This marks an intensified regulatory focus on protecting branded therapies and patient safety.
2. Shares Rebound on FDA News
Novo Nordisk ADRs climbed 4.7% in early Friday trading, recouping losses from the prior two sessions. Traders cited renewed confidence in Novo’s market monopolies for approved weight-loss and diabetes treatments.
3. Hims & Hers Launches $49 Pill
Telehealth provider Hims & Hers rolled out a compounded semaglutide pill at $49 per month, undercutting standard injectable prices by over 80%. The move intensified competition in the fast-growing GLP-1 weight-loss segment.
4. Novo Signals Legal Challenge
Novo Nordisk criticized the Hims & Hers product as unapproved and potentially unsafe, indicating it would pursue legal remedies. The company aims to defend its patent portfolio and maintain exclusive distribution rights.